A recent study from Creighton University and UCLA, researchers found a new drug that holds exciting possibilities for the treatment of cancers and many other diseases.
The new drug HM-10/10 is developed from proteins used to diagnose ovarian cancer. It has been effective in inhibiting tumor growth in colorectal and ovarian cancers in mice.
HM-10/10 is an artificial peptide that mimics high-density lipoprotein (HDL), the so-called “good cholesterol.”
The study is published in the Journal of Cancer Research and Therapeutic Oncology. The lead author is Robin Farias-Eisner, MD, Ph.D.
In the study, the team fed mice with a diet that included the HM-10/10 peptide, and they found these mice had much lower tumor risks than mice that had not eaten the peptide.
The drug also shows the potential to treat other pro-inflammatory diseases, such as macular degeneration, heart disease, Alzheimer’s, and endometriosis.
Prior to publishing on its effectiveness as a cancer treatment, the team published another paper showing HM-10/10’s potential to treat retinal disease (e.g. macular degeneration).
The team previously discovered the depletion of a certain protein, ApoA-1, in ovarian cancer patients created a hospitable environment for cancer to thrive.
With this in mind, the team created HM-10/10 using elements of the ApoA-1 protein alongside other constituent proteins.
Copyright © 2020 Knowridge Science Report. All rights reserved.
